#Cervical cancer vaccine cost in India

[rgcircofficial]

Cervical cancer vaccine cost in India

At Rajiv Gandhi Cancer Institute and Research Centre in India, the cost of cervical cancer vaccines cost varies based on the type and dosage regimen chosen. The institute offers vaccines aimed at preventing cervical cancer, with prices tailored to make them accessible to a wide range of patients. They prioritize public health by providing options that meet international standards for safety and efficacy. Rajiv Gandhi Cancer Institute ensures comprehensive vaccination services, supporting women's health initiatives with expert guidance and affordability, promoting widespread immunization against HPV infections to reduce the incidence of cervical cancer across the country.

For more information: https://www.rgcirc.org/clinical-services/surgical-oncology-services/gynae-oncology-services/cervical-cancer-treatment/

[drpreetirastogigurgaon]

Cervical Cancer Treatment in Gurgaon 

Dr. Preeti Rastogi offers comprehensive cervical cancer treatment in Gurgaon. She provides personalized care using the latest medical advancements. Her approach includes early detection through Pap smears and HPV tests, followed by a detailed diagnostic process involving colposcopy and biopsies if necessary. Treatment options under Dr. Rastogi’s care may include surgery, radiation therapy, chemotherapy, or a combination of these, tailored to the stage and specifics of the patient’s cancer. Emphasizing a holistic approach, she ensures her patients receive not only medical treatment but also support for their overall well-being throughout the cancer journey

What is the HPV vaccine, and how does it prevent cervical cancer? The HPV vaccine (Human Papillomavirus vaccine) helps protect against the types of HPV that most commonly cause cervical cancer. By preventing HPV infections, the vaccine reduces the risk of cervical cell abnormalities, which can develop into cancer over time.

What is the papilloma vaccine? The papilloma vaccine is another term used for the HPV vaccine. It protects against the Human Papillomavirus, which is responsible for causing genital warts and cervical cancer. Regular vaccination can significantly reduce the risk of developing these conditions.

Who should get the cervical cancer vaccine? The cervical cancer vaccine is recommended for girls and boys starting from the age of 9 to 14 years. It is most effective when administered before an individual becomes sexually active and exposed to the HPV virus.

What is the best age to get the HPV vaccine? The ideal age to receive the HPV vaccine is between 9 and 14 years for both boys and girls. Vaccination at this age ensures maximum protection before exposure to the virus. However, catch-up vaccination can still be given up to age 26.

Can the HPV vaccine cure cervical cancer? The HPV vaccine is a preventive measure and cannot cure cervical cancer. It works by preventing new HPV infections but does not treat existing HPV infections or cervical cancer. Early detection and appropriate cervical cancer treatment are essential for curing the disease.

How effective is the HPV vaccine in preventing cervical cancer? The HPV vaccine is highly effective, preventing up to 90% of HPV-related cancers when given before exposure to the virus. It is most effective when the full vaccine series is completed according to the recommended schedule.

Is there a cure for cervical cancer? There is no guaranteed cure for cervical cancer at advanced stages, but it can be treated effectively when detected early. Treatment options include surgery, radiation therapy, and chemotherapy. Regular screenings, such as Pap tests, are crucial for early diagnosis and successful treatment.

What are the common side effects of the HPV vaccine? The HPV vaccine is generally safe and well-tolerated. Common side effects include pain or swelling at the injection site, mild fever, headache, and dizziness. Serious side effects are extremely rare.

How much does the cervical cancer vaccine cost? The cervical cancer vaccine price varies depending on the region and healthcare provider. In India, it typically ranges from ₹2,500 to ₹4,000 per dose. Since the complete vaccination requires 2 to 3 doses, the total cost can be higher.

What are the symptoms of cervical cancer? Cervical cancer symptoms often appear in the later stages and may include abnormal vaginal bleeding, pelvic pain, pain during intercourse, and unusual vaginal discharge. Regular screening tests like Pap smears and HPV tests are crucial for early detection.

How is cervical cancer diagnosed? Cervical cancer is diagnosed through a combination of screening tests such as Pap smears and HPV tests, followed by a biopsy if abnormal cells are detected. Early diagnosis is critical for effective treatment and a higher chance of recovery.

What is the treatment for cervical cancer? Cervical cancer treatment options depend on the stage of the cancer. Early-stage cervical cancer may be treated with surgery alone, while advanced stages may require a combination of surgery, radiation therapy, and chemotherapy.

[felixhealthservice]

Cervical Cancer Vaccine Cost in Noida

The cervix, situated at the lower end of the uterus, serves as the link between the uterus and the vagina. Cervical cancer, which impacts the cells in this area, is predominantly triggered by the Human Papilloma virus (HPV). In India, cervical cancer accounts for about 16.5% of all cancer cases, making it the second most prevalent cancer among women following breast cancer. Fortunately, cervical cancer is preventable through precautionary measures and vaccination.

While unprotected sexual activity with multiple partners is a primary risk factor, it's crucial to understand that not every individual infected with HPV will develop cervical cancer; specifically, only HPV-16 and HPV-18 strains are implicated. Other potential contributors to cervical cancer may include smoking, multiple pregnancies, and early initiation of sexual activity. It's important to note that HPV can affect both men and women, particularly if either engages in unprotected sex with multiple partners.

The cost of cervical Cancer Vaccine in Noida India may vary from Rs 3927/ to Rs 10,850.

cervical cancer vaccine cost starting price is Rs 3927/- (per dose)

cervical cancer vaccine cost average cost is Rs 5500/- (per dose)

cervical cancer vaccine cost maximum cost is Rs 10,850/- (per dose)

Conclusion

Felix Hospital is the best choice for HPV Vaccine in overall aspects, and what makes it even more preferred by the people is our cost aspect. Yes, you heard it right. Felix Hospital offers an affordable  cervical cancer vaccine price or vaccine for cervical cancer price.

Resource: https://www.felixhospital.com/blogs/decoding-the-cervical-cancer-vaccine-cost-in-noida

[indiamedicaltourism]

Cervical Cancer Treatment Cost in India - Are you facing cervical cancer problem? Cervical cancer treatment in India encompasses comprehensive approaches, including screening through Pap smears and HPV tests. Affordable surgical interventions, radiation therapy, and chemotherapy are available. National initiatives emphasize awareness, vaccination, and accessible care, contributing to a proactive strategy in managing cervical cancer, promoting early detection, and improving overall outcomes.

[innovationtrends]

Cancer Vaccines Market Size, Share, Analysis Report by Types, Applications and Forecast 2027

According to our new market research study on "Cancer Vaccines Market to 2027 – Global Analysis and Forecast by Technology, Type, Indication, and End User," the market is expected to reach US$ 15,845.59 million by 2027 from US$ 4,568.82 million in 2019; it is estimated to grow at a CAGR of 17.2% from 2020 to 2027. The report highlights trends prevailing in the global cancer vaccines market, and the drivers and restraints pertaining to the market growth.

Grab PDF to Know More (Including Table, Full TOC and Figures) @ https://bit.ly/40iZbpi

Based on technology, the cancer vaccines market is segmented into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, and viral vector cancer vaccines. In 2019, the recombinant cancer vaccines segment accounted for the largest share of the market, and it is further estimated to register the highest CAGR during the forecast period. Growth of the market for this segment is attributed to the escalating demand for effective vaccines and rising prevalence of cancer. In addition, strategic activities by service providers such as collaborations, mergers, acquisitions, and expansions are further accelerating the growth of the market.

The global cancer vaccines market growth is mainly attributed to factors such as increasing incidence of cancer worldwide, and rising number of initiatives taken by healthcare research organizations and key cancer vaccines companies. However, a limited number of commercially available vaccines for treatment of cancer and higher cost of cancer vaccines hinder the market growth.

CSL Limited, ADURO BIOTECH INC., Astellas Pharma Inc., Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, Glaxosmithkline Plc., Dendreon, ASTRAZENECA PLC., and OSE Immunotherapeutics are among the leading companies operating in the cancer vaccines market.

Cancer is among the leading cause of deaths across the globe and is profoundly affecting the quality of life. Thus, cancer would be a burden on society if not diagnosed and treated on time. According to the World Health Organization (WHO), in 2018, approximately 9.6 million deaths reported across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US. Approximately, 1.9 million new cancer cases and 693,000 cancer deaths were recorded in 2018, in North America. Prostate cancers are the most commonly diagnosed cancers among males in North America; however, breast cancer remains the leading cancer in females. As per the estimations by the American Cancer Society, breast cancer is the most common type of cancer in the US as it caused morbidity in ~234,087 people and lead to 41,904 deaths in 2018. Further, ~276,480 new cases are expected in the country in 2020. As per the Globocan 2019 report, in Germany, the total number of breast cancer cases in 2018 was 71,888, and the disease lead to ~19,376 deaths in that year. Additionally, lung cancer remains the most common cause of death in both sexes. It is estimated that the number of new cases of cancer incidence is 439.2 per 100,000 men and women per year. According to the National Health Profile, the cases of common cancers, including cervical, oral, and breast cancers have increased by 324% in India between 2017 and 2018.

Table of Contents                     

Report Overview: It includes the objectives and scope of the study and gives highlights of key market segments and players covered. It also includes years considered for the research study.

Executive Summary: It covers industry trends with high focus on market use cases and top market trends, market size by regions, and global market size. It also covers market share and growth rate by regions.

Key Players: Here, the report concentrates on mergers and acquisitions, expansions, analysis of key players, establishment date of companies, and areas served, manufacturing base, and revenue of key players.

Breakdown by Product and Application: This section provides details about market size by product and application.

Regional Analysis: All of the regions and countries analyzed in the report are studied on the basis of market size by product and application, key players, and market forecast.

Profiles of International Players: Here, players are evaluated on the basis of their gross margin, price, sales, revenue, business, products, and other company details.

Market Dynamics: It includes supply chain analysis, analysis of regional marketing, challenges,

Continued....

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876

Email: sales@theinsightpartners.com

[newslobster]

Cervical Cancer Vaccine Could Be Developed In India by April-May 2023: Medical Panel Chief

Cervical Cancer Vaccine Could Be Developed In India by April-May 2023: Medical Panel Chief

Dr Arora said that almost 80,000 cases of cervical cancer occur in India every year. (Representational) New Delhi: The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country, said Dr NK Arora, chairman of the Covid working group, National Technical…

[doctor-atp]

Lets talk HPV!

I know people want me to probably talk about vaccine that cures the pandemic we are going through. But let's come to that some other time.

I would like to mainly concentrate on vaccine against HPV (Human Papilloma Virus) as it's the most underrated vaccines of our times. This virus causes a type of cancer in one of the part of the uterus (mainly cervix). It creates an environment and adapts into the environment of the cervix which leads to cellular changes and leads to a precancerous state which if not taken care of may lead to Cervical cancer over later years of your life.

I personally feel, the gap in this knowledge is pertaining to the restrictions of the type of culture we are born and brought up in. A typical Indian Family or Mother/Father to daughter/Son discussion will probably be as follows:

"Beta, you are 21 years and almost have reached an age where you should get married"

In Rural India, forget if they even can reach their 20's, and they get rid of their daughters even before that.

Not even a single mother or father talks to their children about having an healthy approach to their Sexual Activities. This not only applies to teenage groups but also to those belonging to an age group between 21-29 years and upto 65 years of age group. There is a stigma, still there is persistent hesitation among people/communities with respect to approaching Doctors for the same.

So as a Gynecologist it's my responsibility to first create an awareness about this healthy approach and it has to begin with Screening.

What is this screening process?

It's called Pap-Smear /cervical cytology (low cost/ free at varied institutions)

*This Screening begins at the age of 21 years regardless of any particular risk factors.

*This should be continued at an interval of 3 years upto the age of 29 years.

*If you are beyond 29 years... you need to take the screening every 3 years upto the age of 65 years atleast.

A screening is called adequate when 3 pap tests done back to back are negative in the prior 10 years with most recent within 5 years.

This is necessary because the whole process of Viral infection turning into precancerous to cancerous state takes a long process.

Ofcourse there are many more things to this which cannot be discussed at this platform.

You can definitely stop the screening after the age of 65 years.

Something much easier is always around the corner isn't it.

Why not take the vaccine instead?

HPV vaccine is the most reliable and the most promising vaccine, have excellent safety profiles, well tolerated, and can be administered with other recommended vaccines.

Three HPV vaccines are FDA approved:

-Cervarix (Against serotype 16 and 18)

- Gardasil (Against serotype 6, 11, 16 and 18)

- Gardasil 9 (Against serotypes 6, 11, 16, 18, 31, 33, 45, 52, 58)

You can opt the vaccine based on the number of serotypes it covers, with Gardasil 9 being the best.

******Age group:

******Should be ideally given to girls at the age of 11-12 years (as early as 9 years),

Can be recommended for women not vaccinated at an early age as well upto ***45 years of Age.

IT IS NOT RECOMMENDED DURING PREGNANCY, BUT CAN BE GIVEN DURING BREAST FEEDING PERIOD.

No booster dose required as well.

You will receive 3 doses, (Intramuscular) over a period of 6 months

First dose: 0 dose

Second dose: after 2months of the first dose

Third dose: this final dose is given 6 months after the First dose.

So Folks (again sorry for this informal address).........So Husband's - Talk to your wife, talk you your partner, Mother's/Father's : Talk to your daughter/son, about this and spread this bit of awareness from your end too. Have a conversation on long journeys, during train travels, probably during office lunch hours, a long lost busy friend who you are video chatting with..... and create awareness within and in the surrounding bu asking just one question? Did you try protecting your/her "Cervix"?

~ Dr.atp

P.S.: "I belong to the community of Doctors where I have a Right to Freedom of Speech when it comes to creating awareness"

[paullui2002]

Human Papillomavirus (HPV) Vaccine Market: Growth opportunities through 2028

According to our new research study on “Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Dosage, Age, Application, and Distribution Channel,” the market is expected to grow from US$ 4,273.84 million in 2022 to US$ 5,730.50 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2022 to 2028. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the global market growth.

Factors such as increase in prevalence of HPV associated diseases and rise in initiatives by global health organizations drive the overall human papillomavirus (HPV) vaccine market growth. However, the high cost of HPV vaccines hinders the market growth.

Get sample PDF Copy of Market at @ https://www.theinsightpartners.com/sample/TIPRE00029411/

The increase in programs for HPV awareness is one of the effective strategies to increase the vaccination uptake and eliminate HPV-associated cancers.

Dana-Farber Cancer Institute, Boston, US, has initiated the HPV and Related Cancers Outreach Program, which aims to reduce the HPV-related cancer burden in the community through education and vaccination. The outreach program has been developed to address common barriers to vaccination. Through workshops with the City of Boston and the Boston Public Health Commission, youth-serving organizations, Boston Public Schools, Area Health Education Centers organizations, and faith-based and other community-based organizations, people in Boston have been educated about it.

Australian Cervical Cancer Foundation's (ACCF) HPV & Me program is an awareness program that empowers high school students with preventive strategies to eliminate the risks associated with Human Papillomavirus (HPV).

Additionally, in collaboration with computer scientists, HPV-related Epidemiological Research Unit, Norway, developed an innovative approach to communicate the importance of cervical cancer prevention to girls, women, boys, and men of different ages.

Therefore, the market in developing countries is likely to show high growth potential over the next few years.

North America dominated the human papillomavirus (HPV) vaccine market due to the increasing HPV infections and the growing initiatives by governments and institutions for HPV vaccination drive. The US, Canada, and Mexico are witnessing a sequential change in the market. The US accounts the largest share of the regional human papillomavirus (HPV) vaccine market in 2022. Sexual transmitted infection (STI) is the most common infection caused by HPV in the US, and it is often acquired soon after initiating sexual activity. More than 43% of American adults aged 18–59 are infected with genital HPV, with higher rates among men (45%) than women (40%). HPV-related cancers have increased significantly in the past 15 years. In 2015, 43,000 people developed an HPV-related cancer, whereas the count was 30,000 in 1999. While HPV-related cervical and vaginal cancer rates have decreased in recent years, rates for oropharyngeal and anal HPV-related cancers have increased. This increase in HPV infections in the US is mainly driving the growth of the regional market.

GSK; Innovax; Walvax; Serum Institute of India Pvt., Ltd.; Vaccitech; Innovio Pharmaceuticals; Merck & Co., Inc.; 2A Pharm; ChengDu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and BioLeaders are among the leading companies operating in the global human papillomavirus (HPV) vaccine market.  

For more details visit here @ https://www.theinsightpartners.com/reports/hpv-vaccines-market

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: 

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

[nikhilghodse20051994]

Global Cancer Vaccines Market Research, Size, Share, Trends, Global Analysis, 2028 | The Insight Partners

According to our new market research study on "Cancer Vaccines Market to 2027 – Global Analysis and Forecast by Technology, Type, Indication, and End User," the market is expected to reach US$ 15,845.59 million by 2027 from US$ 4,568.82 million in 2019; it is estimated to grow at a CAGR of 17.2% from 2020 to 2027. The report highlights trends prevailing in the global cancer vaccines market, and the drivers and restraints pertaining to the market growth.

The global cancer vaccines market growth is mainly attributed to factors such as increasing incidence of cancer worldwide, and rising number of initiatives taken by healthcare research organizations and key cancer vaccines companies. However, a limited number of commercially available vaccines for treatment of cancer and higher cost of cancer vaccines hinder the market growth.

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis –

https://www.theinsightpartners.com/sample/TIPRE00004595/

CSL Limited, ADURO BIOTECH INC., Astellas Pharma Inc., Merck & Co., Inc., Sanofi, Bristol-Myers Squibb Company, Glaxosmithkline Plc., Dendreon, ASTRAZENECA PLC., and OSE Immunotherapeutics are among the leading companies operating in the cancer vaccines market.

Based on technology, the cancer vaccines market is segmented into dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, and viral vector cancer vaccines. In 2019, the recombinant cancer vaccines segment accounted for the largest share of the market, and it is further estimated to register the highest CAGR during the forecast period. Growth of the market for this segment is attributed to the escalating demand for effective vaccines and rising prevalence of cancer. In addition, strategic activities by service providers such as collaborations, mergers, acquisitions, and expansions are further accelerating the growth of the market.

Click here to avail lucrative discounts on our latest reports. We offer student, enterprise, and special periodic discounts to our clientele. Please fill the inquiry form below to know more -

https://www.theinsightpartners.com/discount/TIPRE00004595/

The Report Segments Global Cancer Vaccines Market as Follows:

By Technology

Dendritic Cells Cancer Vaccines

Recombinant Cancer Vaccines

Antigen Cancer Vaccines

Whole Cell Cancer Vaccines

Viral Vector Cancer Vaccines

By Type

Preventive Cancer Vaccines

Therapeutic Cancer Vaccine

By Indication

Cervical Cancer

Prostate Cancer

Other Indications

By End-User

Pediatrics

Adults

By Geography

North America

 

US

Canada

Mexico

Europe

 

France

Germany

UK

Spain

Italy

Asia Pacific (APAC)

 

China

India

Japan

Australia

South Korea

Middle East and Africa (MEA)

 

Saudi Arabia

UAE

South Africa

South and Central America (SCAM)

 

Brazil

Argentina

Immediate delivery of our off-the-shelf reports and prebooking of upcoming studies, through flexible and convenient payment methods –

https://www.theinsightpartners.com/buy/TIPRE00004595/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense, Food & beverage, Chemical and Materials, Semiconductors etc.

Contact Us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

[research-blogs]

HPV Associated Disorders Market Size 2019-2026 Demand, Global Trend, News, Business Growth, Top Key Players

The global HPV associated disorders market size is expected to reach USD 23.2 billion by 2026, according to a new report by Grand View Research, Inc. It is estimated to exhibit a CAGR of 4.5% over the forecast period, driven by an increase in disease prevalence and emergence of targeted therapies.

Most cancers associated with HPV have high mortality rates. For instance, cervical cancer has a mortality rate of over 50%. Cervical Intraepithelial Neoplasia (CIN) and Anal Intraepithelial Neoplasia (AIN) could advance into cervical and anal cancer, respectively, in the absence of timely treatment. However, these cancers generally have a slow progression rate, providing possibilities for prevention and treatment.

The prevalence of HPV infection-especially in young women-has increased in the recent decades and continues to increase. Globally, cervical cancer stands as the fourth most prevalent cancer in women. Since HPV is a major causative factor for this, the increasing disease prevalence is a key driving force for market growth.

It is estimated that more than 430 million women in India-15 years or above-are considered at risk for developing HPV associated disorders. The annual incidence of these diseases among Indian women is over 122,900 and disease mortality is around 68,000. In the ancillary market of cervical cancer, India records the highest age-standardized disease incidence in South Asia at 22, followed by Bangladesh at 19.2, Sri Lanka at 13, and Iran at 2.8.

Proactive government initiatives and rise in consumer awareness are likely to drive growth. The CDC initiated National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1991. The program was created to promote & and facilitate low-cost or free screening for women. Along similar lines, the Indian government recently started an operational framework for mandatory screening for cervical, breast, and oral cancer in people aged 30 years or more. The initiative marked the first nationwide oncological screening program.

View detailed insights @ https://bit.ly/3B9Vk0A              

 HPV Associated Disorders Market Report Highlights

·         Vaccines remained the mainstay preventive measure against HPV associated disorders in 2018

·         Targeted therapies, such as Avastin and Keytruda, are some of the key revenue generators in the market

·         Nearly three fourths of all cases occur in developing and underdeveloped economies

·         Asia Pacific is positioned to demonstrate the fastest regional HPV associated disorders market growth

·         The CDC recommended the administration of HPV vaccine to adolescents and young adults.

Get Sample PDF Copy @ https://bit.ly/3zehUoh

[indiamedicaltourism]

Cancer Treatment in India at Low Cost

Cancer, an extensive and complicated collection of diseases, develops when abnormal cells grow uncontrollably, breaking their normal boundaries and infiltrating neighboring tissues or organs. Cancer can be present in any organ, including the lung, prostate, colon, stomach, liver, breast, colorectal, lung, cervical, and thyroid cancers. Cancer is the world's second-largest cause of death, taking an estimated 9.6 million lives in 2018.While challenges remain, innovative advances in cancer treatment in India have occurred in recent years, providing greater hope through innovative medicines and increased survival rates.

Some of the groundbreaking innovations in cancer treatment in India are:

Surgery: It involves the precise excision of tumors from specific organs, and is still used as a primary cancer treatment. Surgery success is determined by factors such as cancer type, stage, and location. Surgeons adjust their techniques to eliminate or minimize cancerous development, from modest procedures to major interventions. While advances in surgical procedures have improved precision and reduced invasiveness, the decision to undergo surgery is determined by the type of cancer and the patient's overall condition.

Robotic surgery: It is a technical leap forward in cancer treatment, allowing for more precision and less invasiveness. Surgeons use robotic arms to perform complicated procedures with greater precision. This method is very useful in surgeries requiring precision, such as prostate or gynecological procedures. While the use of robotic surgery is dependent on criteria such as cancer type, location, and the surgeon's expertise, it has proven to be beneficial in reducing recovery periods and increasing overall patient outcomes.

Chemotherapy: Chemotherapy is a systemic approach to cancer treatment that uses medications to slow or stop the growth of cancer cells throughout the body. These medications are administered intravenously or orally, and target fast-dividing cells, both cancerous and healthy, resulting in side effects. Despite its difficulties, chemotherapy is effective against a variety of cancers, particularly those that have spread. The decision to undergo chemotherapy requires careful evaluation of the cancer type, stage, and overall health of the patient, to find the best balance of effective treatment with minimal side effects.

Radiation Therapy:  Radiation therapy uses high-energy radiation to target and eliminate cancer cells while causing as little damage to healthy tissue as possible. Internal radiation includes placing a radiation source within the body, whereas external radiation focuses rays from outside. Radiation therapy, which is tailored to each patient's specific needs, is an essential component of cancer treatment.

Immunotherapy: Immunotherapy is a cancer treatment that uses the body's immune system to locate and remove cancer cells. Checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are all part of this ground-breaking approach. Immunotherapy boosts the immune response, providing a tailored and long-term approach that is especially effective in difficult tumors.

Bone Marrow Transplant:  A bone marrow transplant is essential in the treatment of blood cancers because it replaces damaged marrow with healthy stem cells. This difficult technique, whether autologous (using the patient's cells) or allogeneic (donor's cells), tries to restore blood cell production while eliminating cancer.

Targeted Therapy:  Targeted therapy involves medications that are particularly designed to target cancer cells, and is often used in combination with chemotherapy. This tailored strategy avoids damage to normal cells by interfering with key molecular processes.

Hormone Replacement Therapy:  Hormone therapy, which is essential in the treatment of hormone-sensitive cancers such as breast and prostate cancer, adjusts hormone levels to stop cancer growth. This technique is adjusted based on cancer type, hormonal sensitivity, and overall patient health by blocking hormonal signals that generate certain tumors.

There are many best cancer hospitals in India. These hospitals offer best cancer treatment at affordable cost. Cancer treatment in India typically costs between $3,400 and $30,000 and includes a variety of methods such as surgery, chemotherapy, radiation therapy, and targeted treatments. The success rate of cancer treatments in India has improved significantly, thanks to advances in medical technology, the availability of qualified doctors and nurses, and an increasing emphasis on early detection and tailored treatment strategies.

Al Afiya Medi Tour is a well-known healthcare and medical tourism company in India. We are offer medical tourism services in India foreign patients. Some of the main countries are Bangladesh, South Africa, Uganda, Zambia, Namibia, Iraq, Kenya, Egypt, Nigeria and so on. We provide free assistance for TURP surgery cost in India, lung cancer treatment, breast cancer surgery cost, stomach cancer treatment in India, liver transplant cost, best hospital for heart valve replacement, bone marrow transplant cost, arthroscopic surgery, best liver transplant hospital, hip replacement, brain tumor surgery cost in India,  kidney transplant cost, liver cancer treatment, best bone marrow hospital in India, heart treatment, blood cancer treatment cost etc.  If you are searching for free medical and healthcare consulting to find the best hospitals and top doctors and surgeons in India for any treatment then contact us- Alafiyameditour.com.

Source: https://alafiyameditour1.blogspot.com/2023/12/cancer-treatment-in-india-at-low-cost.html

[atonjoneslove]

COMMON CANCERS IN INDIAN WOMEN

Cancer is the second leading cause of death globally. The top cancers that affect the Indian population are lung, breast, cervical and colorectal cancer. The Indian Council of Medical Research (ICMR) reports that the most common types of cancer in Indian women are the cancer of the cervix, breast, mouth/pharynx, and esophagus. Breast cancer is now the most common cancer among women in India, accounting for 27% of all cancers among women. Oncologists say there has been a sharp uptick in cases in the last six years. The projected estimated number of breast cancer cases in India by 2020 is approximately 1, 23, 534 which means breast cancer will take unprecedented prominence in the near future. The global average is 500000 cases per year and India contributes nearly 5% of that.

DON'T IGNORE THE SIGNS

Late diagnosis, ignorance about signs, and symptoms of cancer and hesitation to see a doctor further complicate the situation. Cancer is mostly detected in advanced stages such as when women either have a lump or discharge from the breast. Half of the women affected with breast cancer in India see a doctor in stage 3 of the disease. It is important to stay protected against cancer by adopting a healthier lifestyle. Breast cancer cannot be prevented however if it is detected early it is easier to treat. In the past, breast self-examination was advocated to help pick up cancer early. Late age pregnancy and lactation, usage of hormonal pills, changing lifestyle, exposure to radiation, changing lifestyle are some of the reasons for the rising incidence of breast cancer. Most types of breast cancer are easy to diagnose by microscopic analysis and can be treated through pre-emptive surgery, lifestyle improvement, radiation, and medications.

RISK FACTORS

There are many risk factors for cancers which include genetic, environmental, and lifestyle factors including tobacco use, alcohol consumption, and infections like HIV. Tobacco contributes to 10 – 15% of cases of cancer in women. Many of the cancers are associated with diet. Cancers of the breast, cervix, ovary, and uterus together comprise more than 70 percent of the cancers that are found in Indian women. All these conditions have higher chances of survival as compared to men, who mostly suffer from lung or oral cancer due to smoking and tobacco consumption.

BREAST CANCER

It is the most common cancer affecting women in India. It accounts for a whopping 27% of all cancers. Reportedly, 1 in 28 women could develop breast cancer. In the rural areas, the number is on a relatively lower side with 1 in 60 women at risk of developing cancer but in the urban areas, it is about 1 in 22 women. Females of any age can develop this cancer and with age the risk increases.

CERVIX CANCER

In South India, cervix cancer is the most prevalent cancer. The global average is 500000 cases per year and India contributes nearly 5% of that. Gynecologic cancers have seen an increase and contribute around 30% to the total cancers in women. The cervix cancer is closely followed by ovarian cancer and corpus uteri which affect a large number of women. Cervical cancer can be caused by a virus (Huma Papilloma Virus). A vaccine is available against cervical cancer.

OVARIAN CANCER

Ovarian cancer mostly affects women when they are 35 years old and reaches a peak when they are between the age of 55 and 64 years. Ovarian cancer affects those women who never had children or those who had children after 30 years of age. Moreover, women with a family history of breast cancer, ovarian cancer, HNPCC, or Hereditary Non-Polyposis Colon Cancer are susceptible to this cancer. Regular health examinations and going for relevant tests could help in identifying ovarian cancer.

COLORECTAL OR COLON CANCER

Women with a family history of colon cancer, suffering from inflammatory bowel disease, or having polyps in their rectum or colon are more at risk of developing colon cancer. Other causes of colon cancer may include being overweight, having high-fat content foods especially derived from animals, being inactive, and smoking. Women between the ages of 40 - 45 years are mostly affected by colon cancer.

WHAT SHOULD YOU DO?

It is important to go for annual cancer screenings. This would not only reduce the mortality rate but improve the quality of life after undergoing cancer treatment. Make important lifestyle changes and start eating nutritious food that includes vegetables, fruits, and whole grains. Start taking Vitamin D and calcium-rich foods or supplements. Maintaining a healthy weight, limiting alcohol consumption, and no smoking could reduce the risk of colon cancer.

The negative effects of cancer are far greater than the mere number of cases. Once a person is diagnosed with cancer, there is emotional trauma followed by the cost of the treatment that causes economic disarray and stress. We recommend women to go for regular check-ups and conduct regular diagnosis for early detection of cancer symptoms and address it to enjoy a complete life. Book an appointment with the best gynecologists in Chennai at PFRC.

[mrunalnerkarblog]

Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $ Billion By 2027

Human papillomavirus infection is most common sexually transmitted infection caused by HPV-related cancers such as cervical and genital cancer. Human papillomavirus infection vaccines are used to prevent genital wart, anal cancer, cervical cancer, and vaginal cancer. Three commercially available HPV prevention vaccine such as Gardasil and Gardasil 9 by Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc, are proven to be highly effective in preventing of HPV infection and genital precancerous lesions. The adoption of preventive vaccines shifted the paradigm of diseases, and are expected to have a major impact in reducing the burden of cervical cancer, HPV-associated malignancies, and benign tumors. The key factors driving growth of the human papillomavirus infection vaccine market include large number of pipeline products, increasing research for therapeutic vaccine, governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.

Request for Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/1588

Human Papillomavirus (HPV) Infection Vaccines Market Driver

Large number of clinical trials conducted by pharmaceutical and biopharmaceutical companies are expected to fuel growth of the HPV infection vaccine market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Currently studies are in phase I clinical trial. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Moreover, increasing research on therapeutic vaccine for treatment of HPV infection to address unmet medical need is expected to boost growth of the human papilloma virus (HPV) infection vaccines market. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated phase 3 in June 2017.

Governmental and non-governmental organization plays important role in increasing awareness through immunization program, in turn driving growth of the human papillomavirus infection vaccine market. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Programme was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Furthermore, global HPV-related disease burden is expected to drive growth of the human papillomavirus (HPV) infection vaccines market. According to National Cancer Institute, 2015, HPV type 16 and type 18, causes around 70% of cervical cancer and is responsible for almost all cervical cancer. According to American Society of Clinical Oncology (ASCO), in 2017, an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4,210 deaths every year. According to World Health Organization (WHO), 2014, HPV type 6 and type 11 are responsible for 90% of the anogenital warts.

Human Papillomavirus (HPV) Infection Vaccines Market Restrains

The human papillomavirus infection vaccine market is expected to constrain by limited number of Food and Drug Administrations (FDA) approved commercial vaccines. High cost of vaccine development is also expected to hinder the human papillomavirus (HPV) infection vaccines market growth over the forecast period. Moreover, variable immunization coverage is estimated to impact the regional size. For instance, economies such as U.K and Mexico has 80% vaccination coverage whereas full-dosage coverage remains below 50% in France and in the U.S.

Human Papillomavirus (HPV) Infection Vaccines Market Regional Analysis

Regional segmentation of human papillomavirus (HPV) infection vaccine market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America comprises major share of the human papillomavirus infection treatment vaccine market, owing to high prevalence of cervical cancer, local market players and increasing governmental initiatives, followed by Europe. For instance, according to WHO 2016, currently 86% of America and 62% of European region girls have access to free HPV vaccination. Moreover, incidence of cervical cancer in Europe was 58,348 individuals per million in 2012. However, Asia Pacific is expected to witness significant growth during forecast period, due to awareness among the population for immunization.

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1588

Human Papillomavirus (HPV) Infection Vaccines Market Key Players

Major players operating in the HPV infection vaccine market include Merck & Co., Inc. and GlaxoSmithKline plc. The companies having the candidate for HPV vaccines are Shanghai Bovax Biotechnology Co., Ltd., Profectus BioSciences, Inc., 2A Pharma AB and ISA Pharmaceuticals.

Human Papillomavirus (HPV) Infection Vaccines Market - Taxonomy

By Product

Gardasil

Gardasil 9

Cervarix

Other Vaccines

By End Users

Hospitals

Clinics

Healthcare Centers

Other

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

[kunalcmi]

INDIA IMMUNE-ONCOLOGY DRUGS MARKET ANALYSIS  - (2018-2026)

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immune-Oncology Drugs Market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/2631

Download PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/2631

Key features of the study:

This report provides in-depth analysis of the India Immune-Oncology Drugs Market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

[fitcancer]

Cervical cancer is preventable. Regular screening (pap smear test) and vaccination helps in curing the patient. Faith in tomorrow cancer foundation initiates proper access to pap smear test and HPV vaccine at lower cost and makes sure it should be easily accessible to women all over India. Need to talk? Contact our oncologist - 999917026 (free of cost) Email - programmedirector@fit-cancer.org #Cancer #cancersurvivor #cancerawareness #cancerresearch #cancerfree #cancerfighter #cancerwarrior #cancersupport #cancerprevention #cancersurvivors #cancers #cancercare #cancercure #cancertreatment #cancerlife #cancergoaway #CancerCenter #cancerpatients #Chemotherapy #selfcare #help #fightcancer #cancercommunity #cervicalcancer #neverstopfighting #fitcancer #faith_cancer https://www.instagram.com/p/CHxXjv3JkO-/?igshid=16ztrxsn7dkx

[abhijeetpawar22]

Cervical Cancer Market 2020: Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2026

Global Cervical Cancer Market Size study report with COVID-19 effect is considered to be an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with the overall size of the Cervical Cancer industry, estimated from 2020 to 2025. The research report also provides a detailed overview of leading industry initiatives, potential market share of Cervical Cancer, and business-oriented planning, etc. The study discusses favorable factors related to current industrial conditions, levels of growth of the Cervical Cancer industry, demands, differentiable business-oriented approaches used by the manufacturers of the Cervical Cancer industry in brief about distinct tactics and futuristic prospects.

Major Players Covered in this Report are: Merck, Advaxis Immunotherapies, Profectus Biosciences, Inovio Pharmaceuticals, Bionor Pharma, ISA Pharmaceuticals, Virometix, Otsuka Pharmaceuticals, Dendreon Corporation, GlaxoSmithKline, F. Hoffmann-La Roche, Zeria Pharmaceuticals

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketgrowthinsight.com/sample/112759

The Cervical Cancer Market study report analyses the industry's growth patterns through Past Research and forecasts potential prospects based on comprehensive analysis. The report provides extensive market share, growth, trends , and forecasts for the 2020–2025 period. The study offers key information on the Cervical Cancer market status, which is a valuable source of advice and guidance for companies and individuals involved in the industry.

The research report will concentrate on leading global players in the Cervical Cancer market report, which includes details such as company profiles, product picture and specification, creation of R&D, distribution & production capability, distribution networks, quality , cost, revenue and contact information. The study report discusses legal strategies, and product development between the industry dynamics that are leading and growing and coming.

Market Segmentation:

The report is divided into major categories comprising product, distribution channel, application, and end users. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Every segment is studied thoroughly in order to offer a better picture to the buyers and stakeholders to benefit from. Information like highest prevailing product, highly demanded product by the application segment and end users are rightly mentioned in the Cervical Cancer report.

Market Breakdown Data by Types:

Chemotherapy

Targeted therapy

Vaccines

Market Breakdown Data by Applications:

Hospitals

Diagnostic centers

Cancer Palliative care clinics

Pharmacies

To get Incredible Discounts on this Premium Report@ https://www.marketgrowthinsight.com/discount/112759

Regional Insights:

The Cervical Cancer market is segmented as North America, South America, Europe, Asia Pacific, and Middle East and Africa. Researchers have thoroughly studied about the historical market. With extensive research, experts have offered details on the current and the forecast demand made by these regions. The Cervical Cancer report also includes highlights on the prevailing product demanded by end users and end customers for better understanding of product demand by producers. This will help the producers and the marketing executives to plan their production quantity and plan effective marketing strategies to more buyers. Businesses can hence, increase their product portfolio and expand their global presence. Cervical Cancer market research report further offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. This will again help the manufacturers to increase their customers and emerge as leaders in the near future.

In this study, the years considered to estimate the market size of Cervical Cancer are as follows:

History Year2015-2019

Base Year2020

Estimated Year2020

Forecast Year2020-2025

Research Objectives

To study and analyze the global Cervical Cancer consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2025.

To understand the structure of Cervical Cancer market by identifying its various sub-segments.

Focuses on the key global Cervical Cancer manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Cervical Cancer with respect to individual growth trends, future prospects, and their contribution to the total market.

If You Have Any Query, Ask Our Experts@ https://www.marketgrowthinsight.com/inquiry/112759

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

Contact Us:

Direct Line: +1 3477675477 (US) Email: sales@marketgrowthinsight.com Web: https://www.marketgrowthinsight.com